Low- versus high-dose interferon alfa-2a in relapsed indolent non-Hodgkin's lymphoma.
VanderMolen
L A
LA
Division of Cancer Treatment, National Cancer Institute, NCI Frederick Cancer.
Steis
R G
RG
Duffey
P L
PL
Foon
K A
KA
Smith
J W
JW
Clark
J W
JW
Conlon
K
K
Stevenson
H C
HC
Urba
W J
WJ
Hartmann
L C
LC
D000328:Adult; D004305:Dose-Response Relationship, Drug; D004341:Drug Evaluation; D006801:Humans; D007370:Interferon Type I / Q000008:administration & dosage*; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000008:administration & dosage*; D008228:Lymphoma, Non-Hodgkin / Q000628:therapy*; D008875:Middle Aged; D011994:Recombinant Proteins
D007370:Interferon Type I; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins